Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Ocular Therapeutix, Inc. on June 1, 2017. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
The primary material event reported is the outcome of the stockholder vote on two matters:
- Election of Class III Directors: Stockholders elected Amarpreet Sawhney, Ph.D., Bruce Peacock, and Jeffrey S. Heier, M.D. to serve until the 2020 Annual Meeting.
- Amarpreet Sawhney, Ph.D.: 12,899,564 votes For; 2,127,299 votes Withheld.
- Bruce Peacock: 12,906,842 votes For; 2,120,021 votes Withheld.
- Jeffrey S. Heier, M.D.: 12,661,305 votes For; 2,365,558 votes Withheld.
- Ratification of Auditors: Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm.
- For: 24,457,147
- Against: 75,696
- Abstain: 5,488
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the tenure of the newly elected Class III directors (through the 2020 Annual Meeting).
- Confirm the appointment of PricewaterhouseCoopers LLP as the independent auditor for the current fiscal year.
- Note the significant number of broker non-votes (9,511,468) regarding the director elections, which may indicate proxy voting restrictions.